Medidata and Bioforum Bolster Decade-Long Relationship to Advance Clinical Data and Biometric Solutions for Clinical Trials
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced a new enterprise agreement with Bioforum, a biometrics CRO that serves clinical trial sponsors worldwide.
Building on more than a decade of collaboration, the expanded partnership provides Bioforum’s biotech customers with broader access to Medidata’s AI-powered technology, enabling a more agile clinical development experience. In addition to Medidata solutions such as Medidata Rave EDC and Medidata Rave RTSM, which Bioforum has leveraged to deliver 60 studies across a range of therapeutic areas, the CRO is adding Medidata Clinical Data Studio and Medidata eConsent to streamline data flow, maintain data integrity, and ensure compliance.
“With our team of experts, industry-leading biometric services, and proprietary technology, Bioforum empowers sponsors to seamlessly manage their clinical data in one place and ensure it’s secure, accurate, and ready for analysis,” said Amir Malka, CEO and co-founder of Bioforum. “We’re excited to be strengthening our alliance with Medidata and, together, providing our customers with the adaptability and advanced solutions they need to thrive.”
“Our expanded partnership with Bioforum brings AI-driven clinical trial management to agile biotech start-ups, accelerating their path to market,” said Janet Butler, executive vice president, head of global sales, Medidata. “By harnessing our Patient Data Surveillance and RBQM platforms, we’re delivering improved operational efficiency for Bioforum and seamless, high-quality data access for their clients.”
Bioforum will sponsor Medidata’s upcoming NEXT New York, a leading clinical trials conference hosted by the company, scheduled for November 13 to 14 in New York City.
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 34,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,200 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com.
© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.
About Bioforum the Data Masters
Bioforum the Data Masters is a leading global clinical research organization (CRO) that specializes in biometric services and solutions for the pharmaceutical, biotech and medical device industries. With a team of experienced professionals and state-of-the-art technology, Bioforum provides a range of services including data management, biostatistics, statistical programming and medical writing to help companies bring new drugs and therapies to market faster. To learn more about us and our services, visit www.bioforumgroup.com or find us on LinkedIn at https://il.linkedin.com/company/bioforum-ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112963841/en/
Contacts
Medidata PR
Medidata.PR@3ds.com
Analyst Relations
Medidata.AR@3ds.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Completes Divestiture of Pharma Solutions Business Unit1.5.2025 09:00:00 EEST | Press release
IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its Pharma Solutions business unit to Roquette. “The completion of our Pharma Solutions divestiture represents a significant milestone for IFF as we delivered our targeted net debt to credit-adjusted EBITDA of below 3.0x,” said Erik Fyrwald, IFF CEO. “This is an important step as it allows us to focus on our core strategy – capitalizing on the exciting growth opportunities within our key businesses – as we maximize long-term value for our shareholders. We’d like to thank our Pharma Solutions colleagues for their unwavering commitment and their dedication to exceptional customer service. We wish them continued success as they find a new home with Roquette.” Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that
More Impact, Together: Varian and Siemens Healthineers Portfolios Highlight More Impact, Innovations and More Breakthroughs Throughout Cancer Care Journey at ESTRO 20251.5.2025 09:00:00 EEST | Press release
Varian, a Siemens Healthineers company, will showcase an integrated portfolio designed to streamline workflows, and aiming to enhance patient experience and improve patient outcomes from screening to survivorship at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual meeting, May 2-6, in Vienna, Austria. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430039992/en/ At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our pers
REI Super Selects SS&C For Superannuation Administration1.5.2025 06:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that REI Super (“REI”), the superannuation fund for Australia’s real estate industry, has signed a long-term agreement to partner with SS&C. REI selected SS&C to serve as the fund’s administrator following a competitive tender process. SS&C Global Investor & Distribution Solutions (GIDS) will provide REI with superannuation administration services and streamlined operations support to its 24,000 members across Australia. REI will benefit from SS&C’s local administration expertise, supported by its global investment in digital service channels, automation and artificial intelligence to enhance the member experience. “As one of Australia’s longest-standing superannuation funds, our focus has always been on serving our members,” said Jarrod Coysh, CEO of REI Super. “SS&C’s extensive track record in fund administration and innovative technology make them the ideal operations partner to help us best meet our members’ needs.” “W
Svante and Mercer International Advance Carbon Capture Project at Alberta Pulp Mill1.5.2025 04:25:00 EEST | Press release
Svante Technologies Inc. (Svante), a leader in carbon capture and removal technology, today announced that its joint carbon capture and storage project with Mercer International Inc. (Mercer) has advanced to the Front-end Engineering and Design Phase 2 (FEL-2). Also known as Pre-FEED, this phase involves engineering, cost estimation, and risk analysis to evaluate the project's commercial viability. Mercer is a global producer of sustainably sourced forest products, including pulp, lumber, mass timber, biomass-based green energy, and bioextractives. The carbon capture project targets biogenic CO2 emissions from Mercer’s Peace River pulp mill, where the biomass (fibre) is sourced from sustainably managed forests. Advancing to the Pre-FEED stage will support further development of the integrated design, cost estimates, and risk assessments—key steps toward a final investment decision and potential implementation. This milestone reflects the growing momentum for carbon capture solutions wi
From Scalable Solutions to Full-Stack AI Infrastructure, GIGABYTE to Present End-to-End AI Portfolio at COMPUTEX 20251.5.2025 04:00:00 EEST | Press release
GIGABYTE Technology, a global leader in computing innovation, will return to COMPUTEX 2025 from May 20 to 23 under the theme "Omnipresence of Computing: AI Forward." Demonstrating how GIGABYTE’s complete spectrum of solutions spanning the AI lifecycle, from data center training to edge deployment and end-user applications reshapes the infrastructure to meet the next-gen AI demands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428101781/en/ From Scalable Solutions to Full-Stack AI Infrastructure, GIGABYTE to Present End-to-End AI Portfolio at COMPUTEX 2025 As generative AI continues to evolve, so do the demands for handling massive token volumes, real-time data streaming, and high-throughput compute environments. GIGABYTE’s end-to-end portfolio - ranging from rack-scale infrastructure to servers, cooling systems, embedded platforms, and personal computing—forms the foundation to accelerate AI breakthroughs across industr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom